Erythromycin A and related compounds, such as clarithromycin, roxithromycin, azithromycin and so on, have poor efficacy against macrolide-resistant bacteria, because organisms with the inducible or constitutive type of cross-resistance to macrolide, lincosamide and streptogramin B (MLS) antibiotics are prevalent. To address this problem, increased effort has gone into developing new macrolides with better activity against these organisms.
Recently, a series of ketolides, in which the 3-cladinosyl sugar residue was replaced by a ketone functionality, were prepared. These ketolides had good in vitro and in vivo activity against erythromycin-susceptible Gram-positive organisms, as well as against erythromycin-resistance organisms. The discovery that the cladinose moiety of erythromycin was not absolutely necessary for good antibacterial activity1) has opened up new areas on the macrolactone ring for SAR exploration. We decided to prepare a compound having an oxime group directly attached to the macrolactone ring at C-9, thus, generating a series of 9-oxime derivatives of the ketolide.
Chemi stry
In this article, we synthesize 3-keto-9-0-substituted pp.506 -509 oxime derivatives of 6-0-methyl erythromycin with a novel method. 6-0-methyl erythromycin A (1) reacted with hydroxylammonium chloride to afford 6-O-methyl erythromycin 9-oxime (2). 2 reacted with benzyl bromide in the presence of sodium hydride at roomtemperature to prepared compound(3), the benzyl group protected the hydroxyl group at the 2'-position and 9-oxime, and the dimethylamine at the 3'-position at the same time. 3 was treated with 1% hydrochloric acid in methanol to give compound (4). 4 was treated with l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDAC) and dimethyl sulfoxide in the presence of pyridinium trifluoroacetate to prepare compound (5)2>3). These protective groups were removed from 5 via catalytic hydrogenation to give compound(6).
In this synthetic route, compound 6 is an important intermediate. Alkylating or arylating the 9-oxime hydroxyl group of the compound6 can give a series of 3-keto-9-(9-substituted oxime derivatives of 6-O-methyl erythromycin A, such as compounds 7-9.
In Vitro Antibacterial Activity erythromycin, but low activity against other erythromycinsusceptible organisms. 4, 5 and 9 do not show increased activity against erythromycin-susceptible organisms, but they have better activity against erythromycin-resistant organisms than erythromycin A. None of the compounds have activity against Gram-negative organisms.
Experimental
Melting points were determined on a Reichert micro melting point apparatus and are uncorrected. 13C NMR spectra were recorded on a Mercurcy-300 spectrometer in CDCI3and chemical shifts are reported in ppmrelative to CDCI3 (77.00ppm) .
Mass spectra were measured with Autospec-Ultima ETOFmass spectrometer.
6-O-Methylerythromycin
A 9-0xime (2) To a solution of 6-<9-methyl erythromycin A (2.5 g, 3.35 mmol) in methanol (1 3 ml) was added hydroxylammonium chloride (2.4 g, 34.8 mmol) and triethylamine (2.4 ml, 17.3 mmol) , and then the mixture was stirred under reflux for 24 hours, the reaction mixture was poured into water, adjusted pH^9 by adding 20% ammoniumhydroxide and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (MgSO4) and evaporated under reduced pressure to give 2 (2.2g, 2.89mmol) as a white 
oxo Erythromycin (7) To a solution.of6 (0.20g, 0.33 mmol) in DMSO-THF(2 ml:2ml) were added 82% KOH powder (25mg, 0.37 mmol), and the mixture was stirred for 10minutes, then was added benzyl chloride (60^1, 0.52mmol), stirred at room temperature for 15 hours. The reaction solution, after addition of H2O (10ml), was extracted with EtOAc (15 mix2). The combined organic layers were washed with H2O and brine, dried (MgSO4) and evaporated under reduced pressure. Using the procedure, following derivatives were obtained.
